SCHEMBL21458194

SCHEMBL21458194

N#Cc1cccc(-c2ccc(Cn3ncc4c(Cl)ccc(C(=O)NC5CC6(CC(CC(=O)O)C6)C5)c43)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.39
CNR2 P34972 2/20 0.36
PRKAA2 P54646 2/20 0.35
ROCK2 O75116 2/20 0.35
ITK Q08881 1/20 0.35
CHRM4 P08173 1/20 0.35
MMP12 P39900 1/20 0.34
MMP13 P45452 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
PTGER4 P35408 1/20 0.34
AXL P30530 1/20 0.34
MERTK Q12866 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
SCD O00767 1/20 0.33
MME P08473 1/20 0.33
FAAH O00519 1/20 0.33
ADORA1 P30542 1/20 0.33
PDE4B Q07343 1/20 0.33
PRCP P42785 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21482125 1.00 MCHR1 (0.39) MCHR1CNR2PRKAA2ROCK2ITK
SCHEMBL31203500 1.00 MCHR1 (0.39) MCHR1CNR2PRKAA2ROCK2ITK
SCHEMBL21458152 0.93 ROCK2 (0.39) CNR2PRKAA2ROCK2CHRM4EGLN1
SCHEMBL31203572 0.93 ROCK2 (0.39) CNR2PRKAA2ROCK2CHRM4EGLN1
SCHEMBL21458205 0.91 PTGER4 (0.42) MCHR1CNR2PRKAA2ROCK2ITK
SCHEMBL21481808 0.91 PTGER4 (0.42) MCHR1CNR2PRKAA2ROCK2ITK
SCHEMBL26623698 0.91 MCHR1 (0.42) MCHR1CNR2PRKAA2ROCK2ITK
SCHEMBL21482124 0.91 MCHR1 (0.42) MCHR1CNR2PRKAA2ITKCHRM4
SCHEMBL21458121 0.90 PTGER4 (0.39) CNR2ROCK2EGLN1PTGER4
SCHEMBL31203526 0.90 PTGER4 (0.39) CNR2ROCK2EGLN1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US claimed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US claimed
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MCHR1 1023/4885CNR2 3/4885PRKAA2 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.